IMPACT OF HAEMATOLOGICAL ADVERSE EVENTS OF TRIPLE THERAPY IN PATIENTS WITH HEPATITIS C

Pharmacy Department. Virgen de la Luz Hospital. Cuenca

BACKGROUND
Protease inhibitor treatment (PIT) has involved an important advance for patients with hepatitis C (PHC). However, PIT may produce haematological adverse events (HAE)

PURPOSE
To analyse HAE impact in PHC who have been treated with PIT.

MATERIALS AND METHODS
Observational retrospective study (December’12-August’14) of patients with PIT who suffered HAE requiring support therapy (SP) in a general hospital. Data collected:
- Medical record review (Mambrino XXI®): weight, treatment (drug, dose, length treatment) and HAE.
- Database of outpatients (Farmatools®): Direct (due to SP) and theoretical (without HAE) cost treatment per patient.

RESULTS
12 patients began PIT (7 with telaprevir, 5 with boceprevir), 6 (3 male and 3 female) with 53.3±3.2 years medium age suffered from HAE, demanding SP (4 patients with weight ≥75 kg).

TELAPREVIR PATIENTS
2 patients presented NEUTROPENIA within 8th and 12th week.
They reduced pegylated-interferon-α2a doses and they began filgastrim 48IU treatment until 36th and 43rd week, respectively, when they stopped their treatment due to other adverse events (AE)

BOCEPREVIR PATIENTS
2 patients (1 HIV-coinfected) underwent anaemia within 6th and 8th week.
They reduced ribavirin doses. One patient began epoetin-alfa 40000 UI until 7th week when he finished treatment for other AE. The HIV-coinfected patient began darbepoetin-alfa 50-100mcg (treatment finished after 48 week)

1 patient stopped PIT at 7th week for severe neutropenia
He had to reduce pegylated-interferon-α2b doses previously. Afterwards, one filgastrim 30 MUI dose was necessary.

1 patient had severe trombocytopenia in 8th week.
She reduced pegylated-interferon-α2a doses.
Later, he began eltrombopag 25 mg until end PIT (48 weeks)

CONCLUSIONS
Direct cost was 179.439,9€ and theoretical cost 169.674,9€.

50% of patients with treatment with IP needed SP to manage HAE. Direct cost was higher than theoretical cost (6.8%), but they could continue their PIT, although 4 patients had to finish it later because of other AE.

Competing interests: none

Abstract Number: PS-029